We use cookies to improve the performance of our site and optimize it for our users. Customize Cookie Preferences

Sign Up Today and Learn More About OnKure Therapeutics Stock

Invest in or calculate the value of your shares in OnKure Therapeutics or other pre-IPO companies through EquityZen's platform.

Get Started

OnKure Therapeutics Stock (ONKT)

OnKure is a clinical-stage biopharma company developing precision medicines targeting validated cancer drivers.

About OnKure Therapeutics Stock

Founded

2011

Headquarters

Boulder, CO, US

Industries

Software, Artificial Intelligence, Data and Analytics

OnKure is a biotechnology company that commercializes a new cancer therapy based on novel, less toxic kinase inhibitor drugs. The company is engaged in the discovery and development of epigenetic therapies for the treatment of cancer that includes selective inhibitors of histone deacetylases. In pre-clinical models of both hematological and solid tumor cancers, their lead candidate, OKI-179, significantly and safely reduces the growth rate of tumors when dosed by itself or in combination with other targeted therapies. OnKure advances the HDAC3 selective inhibitor OKI-422 into pre-clinical toxicology studies. The company's drug candidates aim to treat patients by targeting malignant cells directly, by working in combination with other small molecule therapies and by priming the tumor microenvironment such that checkpoint inhibition is optimized.

OnKure Therapeutics Press Mentions

Stay in the know about the latest news on OnKure Therapeutics

OnKure Therapeutics Management

Leadership team at OnKure Therapeutics

Co-Founder, President & CEO

Anthony D. Piscopio

Chief Medical Officer

Gail Eckhardt

Locked Features

Join now and verify your accreditation status to gain access to:

  • OnKure Therapeutics current valuation
  • OnKure Therapeutics stock price
  • Available deals in OnKure Therapeutics and all other companies
  • Deal offering documents
  • EquityZen's proprietary data and insights, including
    • Cap tables, which include funding history by Share Class and Liquidity Preferences
    • Company Highlights
    • Business Model
    • Risk Factors
Join Now

How to invest in OnKure Therapeutics stock?

Accredited investors can buy pre-IPO stock in companies like OnKure Therapeutics through EquityZen funds. These investments are made available by existing OnKure Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.

How to sell OnKure Therapeutics stock?

Shareholders can sell their OnKure Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 320K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.

If I invest, how do I exit my investment?

There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.

Why choose EquityZen?

Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."